


Digging Deeper into CDISC's new Global Standard for Plain Language in Clinical Research

Sylvia Baedorf Kassis, MPH MRCT Center sbaedorfkassis@bwh.harvard.edu





Meet the Speaker

Sylvia Baedorf Kassis, MPH


Title: Program Director

Organization: The Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard (MRCT Center)

Sylvia Baedorf Kassis, MPH is a clinical research professional with 24 years of experience in a variety of academic clinical research roles.

Over the past 6 years, she has had the privilege of focusing her career on health literacy and participant engagement efforts in the clinical research space, effectively facilitating initiatives that unite divergent perspectives into deliverables that offer harmonized and practical solutions to realworld challenges.

When Sylvia is not working, she enjoys hiking, paddle boarding, creative writing, painting, and playing the violin.



Disclaimer and Disclosures

• The views and opinions expressed in this presentation are those of the author(s) and do not necessarily reflect the official policy or position of CDISC, Brigham and Women's Hospital or Harvard University.







Agenda

- 1. A Quick Overview of the MRCT Center
- 2. Health Literacy in Clinical Research Timeline
- 3. Introducing the Clinical Research Glossary and Process
- 4. What's Next....

The Multi-Regional Clinical Trials Center (MRCT Center)

The MRCT Center is a research and policy center focused on addressing the conduct, oversight, ethics, and regulatory environment of clinical trials.

Our Vision

Improve the integrity, safety, and rigor of global clinical trials.

Our Mission

cdisc

Engage diverse stakeholders to define emerging issues in global clinical trials and to create and implement ethical, actionable, and practical solutions.







How it all Started – Return of Results...

2013-2017

MRCT Center led efforts to develop resources supporting the return of results and data (aggregate and individual) to participants.

In particular, EU Plain Language Summary requirements prompt conversations about health literacy.

2017 -

cdisc

The guidance document, and related toolkit, was released:

http://mrctcenter.org/wp-content/uploads/2017/03/2017-03-20-MRCT-Return-of-Aggregate-Results-Guidance-Document-3.0.pdf

http://mrctcenter.org/wp-content/uploads/2017/03/2017-03-13-MRCT-Return-of-Aggregate-Results-Toolkit-3.0.pdf



The Multi-Regional Clinical This Center of Brighten and Worker's Hospital and Harvard (MMCC Tenter) Resum of Results workprope deretoped a particular patient downeen for all spaces (e.g., Hodurty, nonprofit, government, scadernic) to address in detail key challenges in returning results and potential iosUcons. The auropsi of creating and disconvinuing general clinical II's result summarises (clinical that participants is to ensure that isoty participants are informed above the trial results, that they know that their participants is on this and paties (clinical and approximation, and that they addressed for wake effect contribution to science and pable health. The foundation of returning aggregate results to participants has been summarized in a grancipies:

- . Participants or their designees should be the recipients of research results summaries
- Returning results to trial participants respects their volunteerism and their partnership in research; we recommend, therefore, that sponsors offer to provide results to study participants for all clinical studies.



Clinical Research

GLOSSARY



. Inspired a Commitment to Health Literacy...

2018-2019 - Developed a publicly available Health Literacy in Clinical Research website www.mrctcenter.org/health-literacy

2019 (to present) – Started designing and delivering health literacy trainings

2020 - Developed COVID-19 research pamphlets https://mrctcenter.org/blog/resources/covid-19-clinical-research-flyers/

2020-2021 – Developed and launched the pilot version of the Clinical Research Glossary through an agile iterative process with stakeholders, including patients and their allies <u>https://mrctcenter.org/clinical-research-glossary/</u>

2022 - Clinical Research Glossary expansion efforts began



GLOSSARY



...Leading to a New Collaboration being Forged

2022 – Collaboration with CDISC began.

2023 - CDISC & MRCT Center partnership officially launched.



https://globalforum.diaglobal.org/issue/april-2023/use-plain-language-toincrease-understanding-the-mrct-center-clinical-research-glossary/





Specific Benefits of Collaboration

The MRCT Center Clinical Research Glossary provides:

- Consistency
- Accuracy
- Reliability
- Transparency
- Trustworthiness



GLOSSARY





The Clinical Research Glossary - Need and Mission

- Before 2020, a resource of consistent, accurate, and simplified definitions for use across the research industry did not exist.
- A need for a unified approach that best supports patients, participants, and their caregivers was identified.

MISSION


Develop a plain language glossary that includes definitions that are:

- Co-created with patients, participants, and caregivers,
- Designed for public understanding,
- Accepted by industry and academic stakeholders across the clinical research ecosystem,
- Used to facilitate clear communication about research.









www.mrctcenter.org/clinical-research-glossary

Baedorf Kassis S, White S, & Bierer B. (2022). <u>Developing a consensus-driven</u>, <u>plain-language clinical research glossary for study</u> <u>participants and the clinical research community</u>. *Journal of Clinical and Translational Science*, 1-20. doi:10.1017/cts.2022.12







Current format for each definition:

Randomization

A way to use chance to place study participants into different study treatment groups.

How to say:
Randomization

STUDY	-	.	-	
PARTICIPANTS	"11"	Т"Т	ΰ	
	Г		1	
	L	~	J	
	•			TREATMEN

USE IN A SENTENCE

Researchers use **randomization** to make sure that study groups are similar and chosen fairly.

MORE INFO

Every participant has a chance to be put into one of the study groups. No one can choose which group a participant is placed in, because it is done by a computer program.

Randomization helps make sure the study groups can be compared against each other at the end of the study. This is a way to avoid bias.





Explaining Randomization in Clinical Trials

Randomization and Bias in Cancer Clinical Trials

If you know of another resource that could help explain this term, please contact us!

Audience:

- Patients, participants, caregivers, and the public
- People who create research materials for a non-technical audience
- Research sponsors and researchers to use common language







Clinical Research Glossary - Expansion Activities

- ~125 new definitions developed this year, plus additional features:
 - Updated, shareable illustrations
 - New section to support participant conversations with study team members
- Diverse Workgroup
 - Development Team (DT)
 - 20+ members
 - Multi-stakeholder, including patient/caregiver advocates
 - CDISC representatives joined in January 2023
 - Review Team (RT)
 - Small group (~6)
 - All patient/caregiver advocates
- Monthly written feedback collection and virtual consensus sessions

















Single sentence definition No complex sentences No long sentences No parentheses, symbols, or abbreviations Short, simple words Tone that is conversational No words or terms that do not change the message of the sentence Active voice whenever possible







Clarity – is the content clear?

Accuracy – is the content accurate?

Consistency – is the content consistent with other similar glossary definitions? **Plain language** – is the content in plain language? **Understandability** – is the content understandable to patients/participants? **Agreement** – does the content agree with other authoritative definitions? **Context** – can the content be used across research contexts? **Other** – are there any other concerns not noted above?

Can I accept this definition?







Refine






Definitions only Expanded participation: youth, patients









An Advocate's Reflections on the MRCT Center Process



R. Bernard Coley Care Partner Advocate



What makes this process work

Robust consideration of usage context Respect for patient perspectives Diversity of experienced perspectives



What this process, and collaboration with CDISC, means for patients

Validated definitions Trustworthy and vetted content Bi-directional knowledge exchange







Clinical Research Glossary – What's Next

- Ongoing relationship building with CDISC
- Continued development of definitions and content.
- Creation of a new glossary website with improved search functionality and usability.
- Launch of the updated MRCT Center Clinical Research Glossary with the CDISC plain language standard in the first half of 2024.
- Exploration of ways to expand the reach of the public review process.
- Ongoing considerations for translation into additional languages.









In Summary

- This collaboration with CDISC offers broadened dissemination and uptake opportunities, and a chance to hear directly from users.
- We are working together to meet the goal of releasing a new website with all our defined words, plus all the definitions available as a CDISC standard, in 2024.
- New content will continue to be developed and added into the foreseeable future.
- We encourage you and members of your network to take part in the Public Review periods.
- We hope you will use and share the Clinical Research Glossary.





Thank you to our Expert Advisory Committee (EAC)

Current Members:

- Annlouise Assaf, Pfizer
- Jay Duhig, Abbvie
- Lori Hall, Legacy Health Strategies
- Julie Holtzople, AstraZeneca
- Barbara Kress, Merck
- Elisabeth Oehrlein, Applied Patient Experience
- Marian Ryan, Institute for Healthcare Advancement
- Karlin Schroeder, Novartis
- Christopher Trudeau, University of Arkansas
- Tianna Umann, Equideum Health
- Robert Weker, Patient Advocate





And a special thank you to our current workgroup

Development Team

Behtash Bahador, CISCRP Rebecca Baker, CDISC Lisa Chamberlain James, Trilogy Writina R Bernard Coley, Advocate Deborah Collyar, PAIR/Advocate Scott Finger, CISCRP Helle Gawrylewski, Hawkwood Consulting, LLC Art Gertel, MedSciCom, LLC Julia Hild, *Boehringer-Ingelheim* Maureen Kashuba, Merck & Co.

Rena Lubker, *Medical University of South Carolina* Keri McDonough, *Syneos* Alice Miller, *Syneos* Erin Muhlbradt, *NCI Enterprise Vocabulary Services* **Marilyn Neault (co-lead), Advocate** Robyn Rennick, *GlaxoSmithKline* Harold Silverman, *argenx* Gloria Stone, *G Stone Connections* Cornelia Weiss-Haljiti, *Boehringer-Ingelheim*

Review Team

Roberta Albany, *Advocate* Jessica Chaikof, *Advocate* Maura Cummings, *Advocate* John Ghidiu, *Advocate* Anne Marie Mercurio, *Advocate* TJ Sharpe, *Advocate* **Desiree Walker (co-lead),** *Advocate*





Thank you to the workgroup members who worked on the pilot

Behtash Bahador Sarah Balay Stephen Carr Jessica Chaikof Lisa Chamberlain James Deborah Collyar Jean-Marc Ferran Helle Gawrylewski Art Gertel Lauren Hamill Shannon Hamill Julie Holtzople

Marilyn Neault Elyssa Ott **Brandis Pickard** Robyn Rennick Marian Ryan T.J. Sharpe Kamila Sroka-Saidi Mary Stober Murray **Gloria Stone** Michelle Teufel Desiree A.H. Walker **Robert Weker**

Clinical Research

MULTI-REGIONAL CLINICAL TRIALS THE MECT CENTER OF BRIGHAM AND WORKSHOSPITA and HARVARD

Learn more and follow us:



MULTI-REGIONAL CLINICAL TRIALS

THE MRCT CENTER of BRIGHAM AND WOMEN'S HOSPITAL and HARVARD



MRCTcenter.org









MULTI-REGIONAL CLINICAL TRIALS THE MRCT CENTER OF BRIGHAM AND WORKS HOSPITAL and HARVARD

Thank You!

Contact me at sbaedorfkassis@bwh.harvard.edu





